text:
oort is a system of intelligent connected devices that lets you control your whole living environment with a single app. Read more
Funding Canceled
Funding for this project was canceled by the project creator on July 9, 2014.
oort is a system of intelligent connected devices that lets you control your whole living environment with a single app.
oort - Internet of Everything
Project by
oort - Internet of Everything
First created | 11 backed
About this project
We're used to tapping our phones and instantly getting the results that we want – whether we're looking for a new restaurant, finding movie times or just checking our email. But when we get home, the process is still pretty primitive. We turn on lights individually, flip on the television and fiddle with the air conditioner.
But what if you could make your phone a remote control for all of those appliances? In the morning, you could tap a button and turn on the coffee machine. As you leave, you could make sure all of the lights are off. And, when you're coming home on a sweltering summer day, you could start the air conditioner so that your home is cool and comfortable by the time you get there.
oort helps you do all of this and more. Through a unique system of beacons and sensors, oort turns your phone into a remote control that has the power to turn off lights, control the temperature and even keep track of objects, pets and people.
All of this is possible thanks to oort's multi-radio WiFi/Bluetooth low energy (BTLE) hub, a true Internet of Things (IoT) hub that connects all beacons, power strips, adaptors and environment sensors to one simple, easy-to-use interface that can be managed right from your phone or an Internet browser.
You can…
- Easily build your own wireless smart home or business – control every appliance with the tap of a button!
- Create reports that show you power consumption & let you save your money.
- Monitor your beacons, whether you're keeping track of valuables or making sure your children got home safely
- Create an affordable home security system with presence sensors which monitor your house while you're away
- Unlike other Internet of Things solutions, oort doesn't only work with some devices – we've designed it to interact with all standard BTLE profiles.
- It's extremely easy-to-use – after downloading the free oort app, users can manage devices and sensors from their iOS or Android. You can also do it by any common web browser.
- Since our beacons work across any environment and device, users can personalize their oort experience to fit their lifestyles, creating action triggers based on their own routines
Oort is the first smart home system that uses Bluetooth to communicate between individual devices. While competitors rely on Z-Wave or Zig-bee to pair products with compatible devices – ultimately reducing how many devices can work with the systems – we're ahead of the curve. Oort can be controlled by the smartphones users already own, and can interact with any BTLE-compatible device in the marketplace.
Competitors often require users to manually integrate devices into a new system. Oort does all of that automatically, which means anyone can build a smarter home and start using oort beacons and sensors within a few minutes.
If you enable oort's connectivity, your phone won't just sense and detect your own devices – it will be able to sense others, allowing you to interact with any BTLE-device.
Our goal is to make sure that oort is not just user-friendly, but also affordable. We priced Hub at $99, so everyone can start building their own personal smart home and unlock the power of the Internet of Things.
oort HUB
oort Hub is the heart of the oort ecosystem. It allows your smartphone to communicate with your smart devices and sensors not just through Bluetooth but also through the Internet. Use the hub as a gateway to check what's going on at home even when you're on vacation across the country. Control individual beacons and sensors as well as whole sets of devices. Access all the data from all of your devices in one place. You won't believe how well it works until you try it yourself.
What can you do with it?
- Control devices connected to hub from anywhere
- Set customized actions when a particular device is in range
- Gather data & create reports of power usage
Do you ever get annoyed when you can't find something? That will soon be a thing of the past. Just attach an oort Beacon to your car keys, pet or cellphone; whatever you regularly lose. You'll always be able to locate them within minutes. With the tap of a button in the app, the Beacon will sound an alert and the location will be displayed on your smartphone. Could it be any easier? Actually we have three types of beacons:
- Standard beacon
- Temperature measuring beacon
- Finder beacon
What can you do with it?
- Set custom alerts to be sent when devices are in range of beacons
- Measure temperature in every environment
- Find your lost belongings, pets and whatever else you like
air quality monitor
Research shows that adults spend on average about 80–90% of their life indoors. The time spent indoors increases for small children, the elderly and the ill. What does that mean? The people with the weakest immune systems are the ones who spend the most time vulnerable to bad indoor air quality.
oort Air Quality Monitor features a set of sensors to help you stay healthy - a temperature sensor, a humidity sensor and most importantly the volatile organic compound (VOC) sensor (patent pending). Monitor your air quality so you know the air you and your family breathe is free of unhealthy levels of over 6000 compounds created by paint, varnishes, adhesives and everyday activities such as cooking and cleaning. Access the results from anywhere using your smartphone or desktop web browser. Join the community of environmentally-aware people and share your air quality information to contribute to a better world. The oort Air Quality Monitor can be an important part of your healthy world.
What can you do with it?
- Keep you & your family safe by monitoring the quality of your air and react when there is an alert
- Measure the humidity & temperature in your living environment
Monitor the power usage of your house, office or factory. Remotely switch off the power to limit the energy consumption. Schedule the process so it's done automatically, for instance when you go to sleep. Generate beautiful, detailed reports on energy efficiency with a variety of easy to use charts and graphs. All with the simplicity of oort. Need US version? European? No problem - we got both! Go green!
What can you do with it?
- Feel secure, save money and energy by remotely turning off all connected devices
oort lamp
Become enlightened and manage all lamps in your home or office by one simple application. Went to bed and forgot to turn the light off? Do it without getting up! Traveling on a long anticipated vacation? Use the lamp to simulate that someone is in the house and keep burglars away. Or maybe you just want to create a specific mood? Control the brightness of your light and do whatever you want
What can you do with it?
- Turn your lamp on or off with simple smartphone app
- Create a specific mood by regulating brightness
- Control it from anywhere with an oort hub
soil humidity sensor
What can you do with it?
- Measure the soil humidity of your plants
- Get notifications when they need to be watered
oort Hub
First working prototype
Actual prototype
Actual prototype
oort connects things using Bluetooth Low Energy with iBeacon profiles. Eventually, it will operate on multiradio, which will make oort the most accurate 3D location system on the market, with tracking beacons ensuring 10-30 cm accuracy. oort uses a WiFi/BLE hub to connect data from beacons to the cloud.
Source: http://www.digikey.com
Source: http://www.digikey.com
An example use of the multi-radio capability of the oort hub supporting the simultaneous use of Bluetooth low energy and WiFi to create miniature gateways. The oort hubs communicate via Bluetooth low energy downstream and WiFi upstream. The WiFi up-stream link is connected to a WiFi router connected further upwards to the Internet services. This scheme may be used to extend the range or the system size.
We will enable interaction with your favorite wrist bands: Jawbone Up, Fit Bit & Nike Fuel. It will allow action triggering between the devices. Let your smart device world react & adapt to you as soon as you appear!
We will develop the tech geek KIT. An open hardware set that will allow you to experiment with our beacons and make various modifications.
We will develop a fully environment friendly & battery less beacon. All backers who support us with more than $499 will receive the oortato kit – the first internet of potatoes device.
Shipping costs:
- T-shirt (US free shipping, outside US - 10$),
- early adopter (US free shipping, outside US - 15$),
- other rewards (US - 10$, outside US - 20$)
Facebook | Google+ | Twitter | Instagram | Pinterest |
For more information visit our website: http://www.oort.in
Risks and challenges
The oort team has designed and built other electronic products. In the team's experience, there are several points in the design, manufacturing and certification processes that could cause delays. We will keep you informed and ensure you know right away if we have run into challenges.
Certification, software and hardware design all have the biggest potential to affect timing. Our goal is to make oort as intuitive and innovative as we possibly can, that means we're putting a lot of hours into working on and improving our software and our hardware. The more innovative the products, the more time we might have to spend getting them certified. Our team will be watching the clock and the process so we have the best chance of delivering with no delays.
Overwhelming demand for oort products might also cause a delay. We do plan to release products to supporters in batches so that the earliest backers are the first to receive their sets.
Finally, there is always the possibility of supplier delays. We use technologies from many different companies in our devices, but we have established relationships with all of them during the prototype creation process. We have also made sure we have multiple pipelines for each part.
Whatever happens along our production timeline, you can rest assured that we will keep you updated on our progress.Learn about accountability on Kickstarter
Have a question? If the info above doesn't help, you can ask the project creator directly.
Select this reward
Pledge $1 or more
About $1.00 USD
32 backers
SUPPORTER – Pledge $1 to show your support. We will keep you updated on our project and give you first crack at special offers when oort launches.Less
Select this reward
Pledge $5 or more
About $5 USD
6 backers
FRIEND – Pledge $5 and show your love to oort. Just like with the supporter level, we'll keep you updated on our project and include you on our special offer list.Less
Select this reward
Pledge $15 or more
About $15 USD
4 backers
BACKER – Want to wear your love of the Internet of Everything on your sleeve? Pledge $15 and get an oort T-shirt.Less
Select this reward
Pledge $25 or more
About $25 USD
20 backers Limited (480 left of 500)
EARLY ADOPTER – We'll send you an oort finder beacon from the very first production run. Use it to track your favorite device, while knowing you've supported a great project and saved some $$ off the expected retail price.Less
Select this reward
Pledge $55 or more
About $55 USD
8 backers Limited (492 left of 500)
STORMCHASER – At this level we'll give you an oort beacon and a temperature beacon. You can track your favorite device and monitor the temperature – inside or outside your home.Less
Select this reward
Pledge $69 or more
About $69 USD
1 backer Limited (499 left of 500)
WIZARD - want to control your electric devices via smartphone regardless of their producer? We will send you an adaptor. The rest is up to you!Less
Select this reward
Pledge $159 or more
About $159 USD
2 backers Limited (498 left of 500)
ILLUMINATOR – Want a conversation piece for your living room? We're offering a unique IoT lamp that can be controlled via your smartphone.Less
Select this reward
Pledge $190 or more
About $190 USD
0 backers Limited (300 left of 300)
BREATH OF FRESH AIR – Worried about allergy season this Fall? You'll get an oort Air Quality Monitor that will alert you to VOCs, Pollen and Mold affecting your home air quality.Less
Select this reward
Pledge $199 or more
About $199 USD
7 backers Limited (493 left of 500)
STARTER KIT - Want to start building your own IoT world? Get oort hub, finder beacon & temperature beacon. The rest is up to you.Less
Select this reward
Pledge $259 or more
About $259 USD
0 backers Limited (30 left of 30)
EARLY BREATH OF FRESH AIR – You'll be one of the first 30 people to receive the oort Air Quality Monitor before the official product launch.Less
Select this reward
Pledge $499 or more
About $499 USD
3 backers Limited (97 left of 100)
OORT GURU KIT – get 1 OORT hub, 2 social beacons + 1 temperature beacon, 1 lamp and 1 OORT Air Quality Monitor. Set it up to control your house or give it away to impress your friends and family with cool IoT gifts.Less
Select this reward
Pledge $629 or more
About $629 USD
3 backers Limited (97 left of 100)
THE WIZARD OF OORT ADVANCED KIT – Want to be an IoT wizard in your home? You can manage so many devices with a wave of your finger over your smartphone that even Harry Potter would be impressed. You'll get 2 OORT hubs, 5 beacons, 1 lamp and 1 OORT Air Quality Monitor.Less
Select this reward
Pledge $1,500 or more
About $1,500 USD
2 backers Limited (48 left of 50)
ULTIMATE WIZARD OF OORT ADVANCED KIT – Want to put together the ultimate IoT package? This level is for you. You'll get 2 OORT hubs, 5 customized beacons, 5 lamps, 2 OORT Air Quality Monitors and a T-shirt.Less
Select this reward
Pledge $10,000
About $10,000 USD
0 backers Limited (5 left of 5)
PARTNERS KIT – Let's talk about what we can create for you.Less
Funding period
- (30 days)


text:
The legislation by Assemblyman Jerry Hill (D-San Mateo) requires members of the California High-Speed Rail Authority board to comply with the financial disclosure and conflict provisions of the California Political Reform Act.
The measure further states that contractors and subcontractors, such as consultants, must disclose their financial interests if they are hired by the authority to conduct peer review studies.
"As we go forward with one of the biggest public works projects in the nation," Hill said, "we need to ensure there is maximum transparency and prevent conflicts of interests."

subset: commoncrawl


text:
annual national conference
March 18 & 19, 2016 Seattle
Power in Action!
Our annual national conference is like no other civic gathering in America. Hundreds of changemakers, activists, and catalysts show up to learn about power, build their networks, and recharge their sense of purpose.
Our theme this year was Citizen Power Now, and over 550 people from 30 states and across the political spectrum joined us. This is a time when citizens are solving problems in new ways, bypassing broken institutions, stale ideologies, and polarized politics. We are part of a movement to rekindle citizenship in America. Join us!
2015 Videos
2015 Speakers
2015 Agenda
Friday March 20
|Opening Reception
|Doors Open. Paul Rucker (Artist)
|The Future of Elder Care: What We Need for a Changing America
|Ai-jen Poo (National Domestic Workers Alliance, Caring Across Generations)
|Plenary Panel
|Dignity and Economic Justice
|Ai-jen Poo, Carmen Rojas (The Workers Lab), Susie Young (SEIU), Silvia Gonzalez (Casa Latina). Moderated by Courtney Martin. Co-presented with Reclaiming Prosperity Series.
|Plenary Panel
|Ferguson and Beyond
|Bukky Gbadegesin & Waylon McDonald (Organization for Black Struggle, St. Louis), Reuben Riggs (St. Louis Students in Solidarity), Jazmine Cañez (Women of Color for Systemic Change), Leslie McSpadden (YouthBuild St. Louis). Moderated by Eric Liu.
|Book Signing
Saturday March 21
|Conference Check-in
|Conference Opening
|How Power Works
|Eric Liu (Citizen University)
|Plenary Talks
|Opportunity Youth United
|National Council of Young Leaders
|Social Disruption and the Sharing Economy
|Matt Kibbe (FreedomWorks)
|Understanding and Dismantling Mass Incarceration
|Alison Holcomb (ACLU)
|Breakout Session I,
choose one
|Opportunity Youth United
|National Council of Young Leaders
|Fight the Power: How Social Media Can Undermine Special Interest Politics
|Matt Kibbe (FreedomWorks)
|Understanding and Dismantling Mass Incarceration
|Alison Holcomb (ACLU)
|Mapping Civic and Creative Power
|Hanmin Liu (Wildflowers Institute) & Janet Seibert (City of Austin)
|Action Civics: Get Off the Sidelines!
|Heather Van Benthuysen (Mikva Challenge)
|A Difficult Conversation: A Dialogue on Race & Inequity Using the Power of Love & Good Questions
|Barbie-Danielle DeCarlo (Coming To The Table)
|Let's Eat, Family-Style!
|Plenary Talks
|Online Conversations to Offline Movement: Changing the Conversation on Gun Violence In America
|Shannon Watts (Moms Demand Action for Gun Sense in America)
|The Peer Effect
|Mauricio Lim Miller (Family Independence Initiative)
|The Power of An Inclusive Economy
|Nick Hanauer (Entrepreneur)
|Breakout Session II,
choose one
|Your Message in a Minute
|Shannon Watts (Moms Demand Action for Gun Sense in America)
|Catalyzing the Peer Effect
|Family Independence Initiative Families
|Flipping the Frame on Prosperity
|Nick Hanauer (Entrepreneur)
|Improving Ourselves, Improving Our World
|Ruthie Ackerman & Asha Curran (92nd Street Y)
|'We The People' and The Climate Movement
|Annie Leonard & Rachel Rye Butler (Greenpeace)
|What is Prison For?
|Lynn Novick (Florentine Films)
|Plenary Discussion
|The Art of Social Change
|Claudia Rankine (Poet) & Robert Schenkkan (Playwright) with Eric Liu
|Conference Closing
|Pastor Patrinell Wright (Total Experience Gospel Choir)
|Closing Reception
|Book Signing
Times and speakers subject to change.Conference Resources
Fisher Pavilion, Seattle Center
We are sold out for 2015. Registration is closed. Stay tuned for registration info for 2016.
Conference Headquarters: Fisher Pavilion at Seattle Center, located west of the Armory & south of the International Fountain. Here's a map of Seattle Center.
Traffic and Parking Alert: Park in a Seattle Center garage or lot — or use public transit. We suggest Seattle Center 5th Avenue Garage near the Gates Foundation on Friday or Saturday. We also suggest the 1st Ave N and Thomas garage on Saturday.
Tips & Resources
Arrive. Check-in. Sign Up! When you arrive at Fisher Pavilion you will pick up your name badge and sign up for breakout sessions (descriptions are below). Space is limited in each breakout, so arrive early to get your first choice.
Food: There will be a reception with light snacks and a cash bar on Friday at check-in, and at the end of the day Saturday. There will be coffee, tea and snacks on Saturday morning. Family-style lunch is provided on Saturday. If you need a full meal on Friday evening or breakfast on Saturday there are many places to eat in the Armory.
Accommodations: There are many hotels in the Lower Queen Anne neighborhood near Seattle Center. Use RoomKey.com to find a good deal on a hotel near Seattle Center.
© 2013 Citizen University. All rights reserved. Design by Timothy Sanders. Development by Project 9 Creative.


text:
See other Vientiane properties
Vientiane Backpackers Hostel
Real Reviews
Real reviews from fellow travellers
These are trusted reviews from guests who have actually stayed here. We hope you find them helpful.
Note: we only give a property a rating once it has received a minimum of 3 reviews.
- Page:1/1
- " Good central location for eating and sightseeing, friendly staff, good breakfast. Just a pity that the reception staff and guests tend to sleep on the soft seating area in the lobby which is also used as the breakfast area and wifi, relaxing area. "
- 01 Sep 2014 Margaret New Zealand
- " Nice,safe and relax..Near to the tourist area,good location. "
- 18 May 2013 Anonymous Thailand


text:
- MeetingsSchedule a meeting
- Special EventsPlan a special event
- WeddingsPlan a weddingEnd of tab panel
OffersFeatured OffersEnd of tab panel
About DoubleTreeAbout DoubleTreeEnd of tab panel
Pack your clubs and plan your next Spokane golf getaway with us!
Your Golf Package includes:
Price includes (1) golf pass for each adult in the guestroom per night. Additional golf passes can be purchased at the front desk.
For more information on the Spokane City and County golf courses, visit www.spokanegolf.org & www.spokanecounty.org/parks/.
DoubleTree by Hilton Hotel Spokane City Center
322 North Spokane Falls Court, Spokane, Washington, 99201, USA
All rates are subject to hotel availability; rate does not include taxes, gratuities or other incidental charges; certain length of stay restrictions may apply. Early departure fee may apply. This offer may not be combined with any other discounts or offers. If you are not interested in making this reservation online, please call our Internet Customer Center at 1-800-774-1500. Please request plan code "PL1".
*COURSES OFFERED: Creek at Qualchan, Downriver, Esmeralda, Indian Canyon, Hangman Valley, Liberty Lake, or MeadowWood. (Golf cart not included.) Guests are responsible for making own tee times. Transportation not provided.


text:
The expansive marshes of Allens Fresh lure paddlers upstream in pursuit of a bald eagle or osprey soaring overhead, a heron stalking the shoreline for prey, or perhaps the rise of a yellow perch or a glimpse of a northern river otter sliding down a marsh bank. Visitors witness the diminishing influence of tide and salinity as they proceed upstream. Brackish tidal marshes of cordgrass transition to fresh tidal marshes of wild rice, rice cutgrass and pickerelweed. The receding tide exposes sandy mudflats that provide habitat for the globally rare Long's bittercress (Cardamine longii, State listed as Endangered) and the rare wetland flower, spongy lophotocarpus (Sagittaria calycina). Beyond the marshes, tidal shrublands and forests of willow oak, green ash, and swamp rose yield to nontidal forests of cherrybark oak, red maple, blackgum and sweetgum.
The marshes and swamp forests of Allens Fresh help to maintain the water
quality of the Potomac River and ultimately the Chesapeake Bay by absorbing
nutrients and chemicals and trapping sediments that run off from roads, farm
fields, and subdivisions. Even so, the sandy, tidal mudflats and rare plants
are threatened by excessive runoff. Allens Fresh comprises more than 250
acres owned by the State and managed by the Maryland Park Service.
Rarity Refuge
Long's bittercress is a small plant of the mustard family named after Bayard Long, a Pennsylvania botanist who discovered it in the early 1900s. Its flowers have no petals, but produce tiny versions of the slender capsules that are typical of this plant family. Fewer than 100 populations of this plant are known to exist worldwide, and Allens Fresh harbors one of only two populations on Maryland's Western Shore.
Triumphant Return
Bald eagles and ospreys are now abundant in Allens Fresh and along the shoreline of Charles County, but this wasn't always the case. The widespread use of DDT and organochlorine pesticides in the mid-1900s led to a severe decline in the numbers of bald eagles and ospreys in the United States. These chemicals became concentrated through the food chain, absorbed by aquatic plants and fish, the birds' preferred food, and caused the birds to produce weak egg shells that broke in the nest or did not hatch. The bald eagle was federally listed as Endangered in 1967. With the ban on DDT in 1972, populations of eagles and ospreys began to recover. In 1995, the bald eagle was federally downlisted to Threatened, and in 2007 it was delisted. Maryland delisted the bald eagle from state regulation in 2010. Between 1997 and 2004, biologists documented a 10-fold population increase in bald eagles in Maryland. By the late 1990s over 3,500 pairs of osprey were thriving in the Chesapeake Bay watershed. Bald eagles and ospreys are now great examples of conservation success stories. As our nation's symbol, the bald eagle continues to be protected under the U.S. Bald and Golden Eagle Protection Act, and both the bald eagle and the osprey are protected under the Migratory Bird Treaty Act.
Click here for a Print Version of this map.
Special Note: Allens Fresh Natural Area is used seasonally by hunters.
From Waldorf: Take US 301 (Crain Highway) south past Waldorf to La Plata. Continue south about 9 miles to MD 234 (Budds Creek Road). Turn left (east) and proceed about a mile to the canoe/kayak access areas on the north side of the road on either side of the Budds Creek Road bridge. Park in one of the access areas; keep alert to oncoming traffic.
Driving directions and aerial views open with Google Maps. For the aerial view button, if an aerial view does not open by default, click on the Satellite icon in the upper right corner and Google Maps will switch to an aerial view of the Natural Area.
Printable Version of Allens Fresh Natural Area
Maryland's Natural Areas
- Guide to Maryland's Natural Areas
- Interactive Map of Natural Areas
- Natural Areas by County
- List of Natural Areas
- Maryland Natural Areas News
- Natural Heritage Program
- Rare, Threatened & Endangered Species
- Natural Plant Communities
- Maryland's Wildlife Diversity Conservation Plan
- Maryland Naturalist Organizations
- Contact Us


text:
Tharpe named new principal of Dacusville Middle School
PICKENS COUNTY - Wanda Tharpe has been chosen to lead Dacusville Middle School beginning in the 2013-14 school year.
Tharpe has served as an assistant principal at Liberty Middle School, also in Pickens County, since 2006.
Before her time at Liberty Middle, she was a social studies teacher at Wren Middle School in Anderson County for 10 years.
"I look forward to working with Mrs. Tharpe as principal of Dacusville Middle School," said Kelly Pew, superintendent of the School District of Pickens County. "She is committed to public education and works well with students, parents, faculty and staff. Wanda is uniquely qualified for the position with 17 years of experience in middle school education. She has proven herself as an educator and administrator during her time at Liberty Middle School, and we look forward to seeing her maintain a commitment to excellence at Dacusville Middle."
Tharpe said, "I look forward to becoming acquainted with the students, parents, and staff of Dacusville Middle, and I'm excited to begin working with the community to build strong relationships that will foster academic excellence in the future leaders of our county and state."
At Liberty Middle, Tharpe led teachers in data-centered professional development meetings, and focused on easing the transition of students from elementary to middle to high schools.
She holds an Associate of Arts degree from Greenville Technical College, a Bachelor of Arts in secondary education in social studies from Clemson University, and a Master of Arts in school leadership and supervision from Furman University. She is a member of the South Carolina Middle School Association, the South Carolina Association for School Administration, the national and state Parent-Teacher Associations, and the AdvancEd Quality Assurance Review Team.
Tharpe will succeed Andy Hooker, who has accepted the position of principal of Hughes Academy of Science and Technology in Greenville County.
Subscribe to the Independent Mail
Need Help? Call us at 1-864-260-1284.
Monday-Friday: 6am-4:30pm / Saturday: 7am-11am / Sunday: 7am-2pm


text:
OSI-Approved Open Source (42)
- GNU General Public License version 2.0 (23)
- BSD License (5)
- GNU General Public License version 3.0 (5)
- GNU Library or Lesser General Public License version 2.0 (3)
- MIT License (2)
- Academic Free License (1)
- GNU Library or Lesser General Public License version 3.0 (1)
- Mozilla Public License 1.1 (1)
- PHP License (1)
- Other License (2)
- Public Domain (2)
- Windows (47)
- Grouping and Descriptive Categories (45)
- Linux (43)
- Mac (21)
- Modern (16)
- Emulation and API Compatibility (4)
Top Apps
- Audio & Video
- Business & Enterprise
- Communications
- Development
- Home & Education
- Games
- Graphics
- Science & Engineering
- Security & Utilities
- System Administration
gTamillOCR- Free, Cross-platform Optical Character Recognition for Printed Tamil text released under GNU GPL .This Free Software uses IPL98 and wxWidgets Cross platform GUI Libraries..9 weekly downloads
AcuDOS is an attempt to revive the PDE MS-DOS Emulator. It aims at emulating the PC hardware and simulating MS-DOS with maximum of accurateness including cycle-exact CPU emulation and support for CGA tweaked modes and true CGA colours.3 weekly downloads
Bidi Editor
Reference implementation for the proposed SII 5194 (Bidirectional Text Editing) Israeli standard (hopefully, a Unicode standard in the future). This is a fully functional text editor with complete BiDi support.2 weekly downloads
sim monster
Un piccolo programma per aiutare il master a gestire i mostri durante un combattimento di D&D (Dungeons & Dragons) edizione 3,5. Ha lo scopo di rendere un combattimeto più snello in caso di avversari numerosi o di diverso tipo.1 weekly downloads
Language Binding of the wxWidgets library to PHP1 weekly downloads
Administrador de Proyectos
Es un Administrador de Proyectos0 weekly downloads
A Development Framework for Coldfire0 weekly downloads
Collaborative Text Editor
The Collaborative Text Editor project aims at creating a powerful, leightweight and platform independent text editing tool for the purpose of concurrent manipulation of shared textual contents in multi-user environments.0 weekly downloads
Diffraction Calculator
Program to simulate, design and optimize different diffractive optical elements, and to simulate the propagation of wave fronts in the Fresnel regime.0 weekly downloads
We are currently developing our embedded Ethernet/CAN/Zigbee libraries wich will target independent microcontrollers for industrial Control and data acquisition systems. Development environment : Windows/Linux and GNU tools like GCC (ASM, C, C++).0 weekly downloads
This tool helps shopkeepers to maintain record of stock & selling item0 weekly downloads
This is a remake of the great game Elite. It lasts 50 years in future of the old game. For people who don't know it: It is like Privateer, X2 and Freelancer. Please read oour documentation. For latest sources use our Subversion-Tree.0 weekly downloads
FlameBin: A Binary NNTP Downloader
FlameBin is a binary file downloader for usenet. It supports multiple servers, simultaneous file downloads and other common usenet binary downloader features. An advantage over other binary downloaders is that it is cross-platform.0 weekly downloads
Golf: Last Lonely Eagle
Golf LLE is a remake of the classic 1992 DOS Golf Game Links(TM) 386 written by Access Software. The game will eventually feature full loading of Links 386 courses and provide a similar gameplay to that of the original game.0 weekly downloads
HAM Team Remote Server and Clients0 weekly downloads
HuGoTaS! - TG-16 Emulator
This project is to first of all port the Turbo Graphics 16 emulator HuGo! GUI to wxWidgets for cross-platform compatibility add tool assisted speed runtools of which there is a proper list located at http://tasvideos.org/DesiredEmulatorFeatures.html0 weekly downloads
Illustration Watermarking Toolkit
Software project to embed additional information into digital images using up-to-date data hiding technology.0 weekly downloads
Integrated Structure Evolution Env.
Integrated Structure Evolution Environment0 weekly downloads
KaitaIRC is a new IRC client which strives for cross-platform compatibility, a rich set of features, and the end-users complete control over how the offered features are used. It differs only because it brings many existing features into one.0 weekly downloads
Kernel Hacking Suite
This project tends to implement a set of kernel hacking utilities, such as filesystem monitoring, process controlling, memory accessing, rootkit subverting, etc. It is designed to be plugin-extensible. Both binary and script plugins will be supported.0 weekly downloads
Lambda is a free software project for store user, clients, friends informations written in C/C++ using wxWidgets and ODBC library.0 weekly downloads
Lua Gnomonic Calculator
A free, portable, plug-in based, gnomonic sundial calculator utility0 weekly downloads
This is a simple (MMO)RPG that is still in the planning/early dev stages, currently done is: player,monster,items Basic game/graphics engine coming SOON!0 weekly downloads
Mess Manager
This project is aimed at providing a automated system for managing a canteen.0 weekly downloads
Mystic Widgets
The goal of this project is to provide a plasticity SDK, i.e. to allow developpers to create UIs that can be displayed on the fly on various devices (other PCs, PDAs, cell phones...).0 weekly downloads


text:
School superintendents discuss challenges of their roles
School district superintendents in Ventura County say low morale, increasing diversity, burdensome regulations and a flawed assessment system are among the challenges they face, in addition to the ongoing fiscal crisis in California that has seen education budgets dramatically reduced.
That was the opinion of several top educators who gathered Thursday evening for a discussion about public school leadership at California Lutheran University in Thousand Oaks.
Jeffrey Baarstad, Conejo Valley Unified; David Gomez, Santa Paula Unified; Ellen Smith, Moorpark Unified, and Trudy Tuttle-Arriaga of Ventura Unified joined Stan Mantooth of the Ventura County Office of Education and Julian Crocker of San Luis Obispo County Office of Education for the discussion. It was moderated by Robert Fraisse of Somis Union School District.
Baarstad, who took over the leadership of the Conejo district last year, said one of the biggest hurdles he faces is dealing with a crisis of public confidence in the public school system.
"It's trying to maintain the morale of staff in the face of a continually shrinking budget and I think just outright hostility by the public and the media," he said. "Somehow, and I don't understand this, now the greatest enemy of the American public is a unionized public school teacher. Go figure."
Gomez pointed out the need for 21st century skills to be included in the curriculum and for the leadership to reflect cultural changes taking place around them.
"We need more diverse leadership and leaders who understand issues related to diversity. We need school leaders able to communicate, not just in English, but in the language of the students and of the community they are engaging," said Gomez.
Smith, who has announced she will retire in June after five years as the leader of Moorpark Unified, said superintendents are laboring under a huge system of constraints.
"I think we have a conflicting, confusing, punitive system of narrow accountability," she said. "I would change the assessment system and I would eliminate the education code and start all over again."
Before the panel discussion, George Petersen, the dean of CLU's School of Education, shared with the audience the findings of "The American School Superintendent: 2010 Decennial Study." Petersen co-authored the report, which was published in December.
The study, sponsored by the American Association of School Administrators, found that about half of the nation's school superintendents plan to retire in the next five years.
He said the research showed women and minorities are under-represented in leadership positions in the public school system and there is a lack of academic preparation among those seeking to become superintendents.
Tuttle-Arriaga, who's been with Ventura Unified for 11 years, said the leadership qualities required in the next generation of school superintendents are people skills and business acumen.
"The first most important skill is being able to relate to other people. That to me is 90 percent of the job," she said. " If you can get along well with people and you communicate well and you can collaborate and bring consensus among people then the rest you can learn."
"We need someone who learns while they are leading and can deal with the media," said Mantooth. "And not just with the media but with interest groups and constituents who want to be heard and want to have their way and aren't used to hearing the word no.
"It's sad that we have to defend an institution that is the bedrock of our society, but that's a critical skill," said Mantooth.
Subscribe to the Ventura County Star
Need Help? Call us at 1-877-710-6182.
Monday-Friday: 6am-3pm / Saturday: 6:30am-10:30am / Sunday: 7am-11am


text:
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. Bleeding is variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, to mild bleeding that requires no treatment. AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated.
Structured literature searches were used to support expert opinion in the development of recommendations for the management of patients with AHA.
Immediate consultation with a hemophilia center experienced in the management of inhibitors is essential to ensure accurate diagnosis and appropriate treatment. The laboratory finding of prolonged activated partial thromboplastin time with normal prothrombin time is typical of AHA, and the diagnosis should be considered even in the absence of bleeding. The FVIII level and autoantibody titer are not reliable predictors of bleeding risk or response to treatment. Most patients with AHA are elderly; comorbidities and underlying conditions found in 50% of patients often influence the clinical picture. Initial treatment involves the control of acute bleeding with bypassing agents. Immunosuppressive treatment to eradicate the FVIII inhibitor should be started as soon as the diagnosis is confirmed to reduce the time the patient is at risk of bleeding.
These recommendations aim to increase awareness of this disorder among clinicians in a wide range of specialties and provide practical advice on diagnosis and treatment.
Acquired hemophilia A (AHA) is a bleeding disorder caused by an autoantibody to factor VIII [1-4]. It must be distinguished from congenital hemophilia, which is an inherited disorder caused by mutations in the FVIII gene that presents at a young age and is characterized by a distinct bleeding phenotype. AHA has an estimated incidence of 1.5/million/year and predominantly affects older patients [5-7]. The disorder presents with bleeding, ranging from life- and limb-threatening to mild in patients with no personal or family history of bleeding, and has a high mortality, estimated at between 9-22% [5,8].
Patients usually present to physicians who are not specialists in the field and have not previously managed a case, typically geriatricians, obstetricians, rheumatologists, oncologists, emergency physicians, intensive care physicians or surgeons as well as hematologists. Lack of familiarity with the disorder may lead to delayed diagnosis and suboptimal treatment, therefore immediate consultation with a hemophilia centre experienced in the management of inhibitors is required, irrespective of the clinical features at presentation [9,10]. The clinical phenotype does not correlate with the factor VIII level or inhibitor titer [1,5], and patients remain at risk of spontaneous, life-threatening bleeding until the inhibitor has been eradicated [5], even if the initial presentation is associated with mild or no bleeding. The age of the patients and associated comorbidities [11] often influence the clinical phenotype and the risk of treatment-induced side effects [1].
There is no high-level evidence to support management recommendations for patients with AHA. Some data generated in patients with congenital hemophilia can be used to support treatment decisions, however, most treatment recommendations rely on the clinical experience of physicians who have managed patients with the disorder [10]. This guideline is intended to increase the awareness of this rare but often fatal disorder among health care professionals to whom patients with AHA usually present. Clinicians who require more detailed management guidelines are referred to other publications [10,12].
Literature searches were performed using the indexed online databases MEDLINE/PubMed using the terms "acquired h(a)emophilia", "acquired factor VIII inhibitors, "acquired inhibitors" and "h(a)emophilia with inhibitors". The full manuscripts from relevant abstracts were retrieved and supplemented by literature from the authors' own libraries. Approximately 150 articles were retrieved and distributed to the author group. The manuscript was written by the authors, coordinated and supported by Physicians World Europe GmbH, Mannheim, Germany. Recommendations were formulated according to the method of Guyatt et al. [13], where "we recommend" represents a strong (Grade 1) recommendation and "we suggest" a weak (Grade 2) recommendation. Because no high or medium-level evidence exists to support management recommendations, the literature cited was not graded according to level of evidence. A parallel manuscript for specialist physicians was also developed [12].
The authors comprise an independent, international medical collaboration with expertise in the field of AHA. The need for increased awareness of the disorder and practice-based guidelines was initially suggested by one member of the author group (CK). The group's activities were funded by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, a company that commercializes recombinant factor VIIa (NovoSeven®), an agent manufactured by Novo Nordisk A/S, Bagsvaerd, Denmark and used to treat bleeding in AHA.
Results and Discussion
Clinical presentation
Patients with AHA tend to be elderly, with a median age of 77 years [11]. The incidence per million per year increases with age from 0.3 in 16-64 year olds to 9 in 65-84 year olds and 15 in those aged 85 and older [5]. Patients with AHA present with a bleeding pattern that is distinct from congenital hemophilia. Severity in congenital hemophilia can be predicted from the factor VIII level, and patients predominantly experience hemarthroses, trauma-induced muscle bleeds and other soft tissue bleeds. AHA patients typically present with widespread subcutaneous bleeds (seen in 80% of cases) and other soft tissue and mucosal bleeding such as muscle hematoma, urinogenital tract bleeding (including post partum) and other mucosal sites. Compartment syndromes associated with neurovascular injury are also seen, however hemarthroses are uncommon (Tables 1 & 2). Bleeds in AHA are often spontaneous, and the severity does not correlate with the factor VIII level [3] or strength of the inhibitor. Severe bleeding following invasive procedures is almost inevitable, and venipuncture commonly results in extensive subcutaneous bleeding. Fatal hemorrhage occurs in about 9-22% of cases [5,8]. In contrast, mild bleeding, requiring no haemostatic treatment, is seen in about 30% of cases [1,5,8,14,15] (Figure 1). Patients occasionally present with abnormal routine blood tests without clinical evidence of bleeding.
Table 1. Characteristic symptoms associated with acquired hemophilia.
Table 2. The distribution of bleeding symptoms in two cohorts of patientsa with AHA.
Figure 1. Extensive subcutaneous ecchymoses of the limbs, thorax and abdomen.
Patients remain at risk of fatal bleeding until the inhibitor has been eradicated, even if they initially present with mild or no bleeding [5]. Early hemorrhagic deaths, within the first week, may result from gastrointestinal or lung bleeding, whereas later deaths are predominantly due to soft tissue bleeding such as intracranial and retroperitoneal bleedings [5].
In about half of patients, an underlying condition is observed (Table 3). Autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, polymyalgia rheumatica, malignancies, dermatologic disease (especially pemphigoid) and pregnancy are common [5,8,14]. Associated medical conditions and treatment may contribute to the clinical presentation and response to treatment.
Table 3. Disease states associated with acquired hemophilia.
We recommend that physicians managing a patient with suspected or confirmed acquired hemophilia A, with or without bleeding, consult a hemophilia centre with expertise in managing inhibitors as soon as possible.
AHA requires specialist clinical and laboratory expertise and facilities for diagnosis and treatment [9,10]. Transfer to a specialist centre is often appropriate. If consultation with or transfer to a hemophilia centre is not immediately possible then investigation and treatment should be initiated while a liaison is being established.
Laboratory investigation
We recommend that a diagnosis of acquired hemophilia A be considered in all patients with recent onset of bleeding and/or an unexplained prolonged activated partial thromboplastin time with a normal prothrombin time.
We suggest use of an algorithm such as that shown in Figure 2 for the differential diagnosis of an isolated prolonged activated partial thromboplastin time (aPTT).
Figure 2. Algorithm to guide the management of patients with suspected acquired hemophilia. AH, acquired hemophilia; LA, lupus anticoagulant; F, coagulation factor; aPTT, activated partial thromboplastin time.
The diagnosis of AHA is suggested by the clinical picture and confirmed by laboratory investigation. First-line investigations for a patient with unexplained bleeding include a full blood count to assess platelet number and a coagulation screen. The typical finding in patients with AHA is a prolonged aPTT with a normal prothrombin time (PT).
Investigation of an isolated prolonged activated partial thromboplastin time
A prolonged aPTT with a normal PT may be due to a deficiency of one of the intrinsic coagulation factors (FVIII, IX, XI or XII) or indicate the presence of an inhibitor. An inhibitor may be against one of the intrinsic factors, most commonly FVIII, but may also be a lupus anticoagulant. Tests for a lupus anticoagulant will be normal in the presence of a FVIII inhibitor, but a lupus anticoagulant may lead to artefactually low factor VIII levels and therefore mimic AHA [16].
Irrespective of the presence or absence of bleeding, an isolated prolonged aPTT outside the normal range should be investigated further. If a patient has bleeding suggestive of AHA further investigation is required even if the aPTT is normal. Some prolonged aPTTs are clinically insignificant but must be adequately investigated to exclude an intrinsic factor deficiency or an inhibitor before this conclusion can be drawn.
Mixing tests
To differentiate between an inhibitor and a factor deficiency, mixing studies with normal plasma are used. In these studies patient plasma is mixed with pooled normal plasma in a ratio of 1:1. If the patient plasma has a prolonged aPTT secondary to a deficiency of a clotting factor then the normal plasma will provide the missing factor and the aPTT will be corrected to normal. If on the other hand a patient has an inhibitor to factor VIII, then the factor VIII in the normal plasma will be inhibited and the aPTT will not correct. Failure of normal plasma to correct the aPTT by more than 50% is usually taken as evidence that an inhibitor is present [17], although in some laboratories other definitions are used, and there is no international consensus. FVIII inhibitors, however, are time- and temperature-dependent because the inhibitor does not inhibit the factor VIII in the normal plasma immediately. Therefore, mixing studies must be incubated for 1-2 h at 37°C [10,18]. A mixing study performed without incubation for 1-2 hours or at a lower temperature may result in correction of the aPTT and the diagnosis of AHA potentially missed. Correction of the aPTT with normal plasma does not exclude a FVIII inhibitor, and if the clinical picture is suggestive of AHA, further investigation is warranted. If mixing tests are compatible with an inhibitor, or the clinical picture is suggestive of AHA, the sample should be urgently referred to a specialist hemostasis laboratory for further investigation by Bethesda assay to measure the strength of the factor VIII inhibitor [19].
The principles of treating AHA are to control bleeding, avoid procedures that may induce bleeds, initiate immunosuppression to eradicate the inhibitor and treat any underlying disease [3,4,9,10,20].
We recommend that invasive diagnostic or therapeutic procedures not be undertaken unless essential and cannot be delayed. Invasive procedures should be undertaken at a hemophilia centre experienced in the treatment of inhibitors.
Patients with AHA should not be subjected to invasive procedures, unless these are essential and cannot be delayed, because uncontrollable bleeding may result from even minor procedures. Venipuncture, the placement of a venous cannula and measurement of blood pressure may also lead to severe bleeding and should be kept to a minimum. Lumbar puncture should not be performed without haemostatic cover. Intramuscular injections are contraindicated. Unavoidable invasive procedures such as the placement of central lines, arterial puncture for blood gas assessment or lumbar puncture should be performed under cover of a bypassing agent.
Treatment of hemorrhage
We recommend that bleeding episodes in patients with AHA be treated in consultation with a hemophilia centre experienced in the treatment of inhibitors.
Many patients require immediate treatment to control bleeding, but not all types of bleeding require intervention [5,15]. The cardiovascular comorbidities associated with advanced age may put patients at risk of thrombotic complications during haemostatic therapy. Factor VIII levels or inhibitor titers are of no value in guiding anti-hemorrhagic treatment [3,4,10].
First-line treatment of bleeding in AHA is with a bypassing agent. The two available licensed treatments are recombinant factor VIIa (rFVIIa, NovoSeven®) [21,22] and the activated prothrombin complex concentrate (aPCC) (FEIBA®; Factor VIII inhibitor bypassing activity) [23]. The treating physician should be experienced in the use of these products [24,25], or should transfer the patient to a centre where this expertise is available. If transfer is not possible, then haemostatic treatment should not be delayed and treatment should be initiated at standard doses while contact with a hemophilia centre is established for advice. Standard treatment with rFVIIa is 90 mcg/kg every 2 h until the bleed has been controlled followed by further, less frequent dosing, to prevent recurrence. FEIBA is dosed at 50-100 U/kg every 8-12 h with a maximum dose of 200 U/kg/day until the bleed has been controlled with additional doses to prevent recurrence.
Data on the efficacy of anti-hemorrhagic treatment are retrospective and include a limited number of patients with a wide range of conditions. Prospective randomized clinical studies that compare the efficacy of the available agents in AHA have not been performed and are impracticable due to the rarity and diverse clinical features of the disorder. A prospective randomized trial of hemarthroses in congenital hemophilia did not demonstrate any difference in efficacy between rFVIIa and FEIBA, although criteria for equivalence were not met [26]. This study must be viewed with caution in the context of AHA because, while hemarthroses are common in congenital hemophilia, they are unusual in AHA. Retrospective studies and clinical experience in AHA show that bypassing agents are effective in about 90% of patients [22,23,26]. In cases where one bypassing agent is ineffective, good efficacy may be achieved with the alternative agent.
The use of bypassing agents in AHA is associated with a risk of arterial thrombosis because many patients have cardiovascular risk factors. A literature review reported that 7% of patients treated with rFVIIa experienced a thrombotic event [22]. The high risk of life-threatening bleeding if bleeds are not treated early and adequately, however, outweighs the risk of thrombosis in most situations, although large subcutaneous bleeds often require no treatment.
Response to haemostatic therapy is usually best assessed clinically and by measurement of the hemoglobin or hematocrit. Radiological imaging sometimes plays a role. There are no laboratory tests that have been demonstrated to be useful for monitoring the efficacy of bypassing agents. After hemostasis has been achieved, further treatment may be required to prevent re-bleeds at the same site.
If the level of the inhibitor is very low and no bypassing agent is available, hemostasis can sometimes be achieved with high doses of FVIII [27]. The response to this treatment, however, is unpredictable and the use of factor VIII should not delay the use of agents more likely to control bleeding. Factor VIII is more efficacious when used as part of multimodal treatment regimens that include immunoadsorption to temporarily remove the inhibitor. However, at the time of writing immunoadsorption columns are not available in all countries, and this therapy is available in only a few highly specialized centers [27-29].
Desmopressin (DDAVP) at a dose of 0.3 mcg/kg intravenously may be useful in the context of minor bleeding episodes and very low titer inhibitors [30-33] but the use of DDAVP should not delay the use of more effective drugs. There is no evidence to support the use of intravenous gammaglobulin as a single agent to resolve bleeding.
Treatment to eradicate the inhibitor
We recommend that all patients diagnosed with acquired hemophilia A receive immunosuppressive therapy immediately following diagnosis.
The risk of fatal bleeding continues until the factor VIII antibody has been eradicated, therefore immunosuppression should be commenced in all patients as soon as the diagnosis has been made [2]. Immunosuppression is best undertaken in consultation with a hemophilia centre experienced in the management of inhibitors, but if advice is not immediately available, treatment should not be delayed.
The optimal strategy for inhibitor eradication is unknown. The two most common regimens are corticosteroids alone or corticosteroids combined with cyclophosphamide (for reviews see [1,9]). Some experts recommend the combination of steroids and cyclophosphamide as initial treatment, asserting that the inhibitor is eradicated more rapidly [20]. However, the published evidence from retrospective studies suggests that neither strategy leads to a superior outcome [1,5,9] and the only randomized study comparing the two regimens did not recruit sufficient patients to be interpretable [34]. Reviews of published data and large cohorts suggest that about 70-80% of patients achieve remission with steroids alone or steroids combined with cyclosphosphamide but studies have variable treatment regimens and different definitions of endpoints and so cannot be directly compared [1,5,9]. We therefore suggest that immunosuppression be initiated with either prednisolone alone at a dose of 1 mg/kg or a combination of prednisolone and cyclophosphamide (1-2 mg/kg).
The median time to remission with corticosteroid treatment is about 5 weeks [9], however if the factor VIII level has not started to increase and the inhibitor titer decline after 2-3 weeks, an alternative immunosuppressive regimen should be considered. If corticosteroid treatment has been initiated and fails to induce remission, commonly used strategies include the addition of cyclophosphamide [1,9,10,34] or rituximab [1,7,34], although rituximab is not licensed for this indication. Third-line therapies include rituximab [35-37], if not already used, or combinations of cytotoxic agents or cyclosporin [38,39]. The side effects associated with these drugs must be taken into consideration, particularly in the context of patient age [11]. Neutropenia with subsequent infections and sepsis have been reported and may contribute to patient mortality [1,5,14,39-43].
Patients may be monitored on an outpatient basis, except in the presence of bleeding or high comorbidity. Patients should be educated about how to report relevant symptoms and access specialist services on a 24-hour basis. Routine monitoring should include physical examination, hemogram, aPTT, FVIII activity and FVIII inhibitor titer assessments. Relapse is seen in up to 20% of patients, and prolonged follow-up is required [5]. Elevated FVIII levels in AHA patients in remission are common, and appropriate prophylactic management in thrombosis-prone patients should be considered during high risk clinical episodes [44]. Thromboembolic risk in general should be managed as in any other patient without a history of a coagulation disorder [45], although there are no studies into thromboprophylaxis in the context of patients recovering from AHA.
Because AHA is a rare but often fatal disorder that usually presents to clinicians without previous experience of the disorder there is often a delay in diagnosis and hence under treatment. Due to the high mortality and morbidity associated with this condition and the complexity of diagnosis and treatment, immediate consultation with a hemophilia centre experienced in the management of inhibitors should be initiated whenever AHA, with or without bleeding, is suspected.
The aim of these recommendations is to increase the awareness of this disorder among health care professionals to whom AHA hemophilia patients are likely to present, encourage timely referral to an experienced specialist physician and create a standardized level of care for this patient group.
List of abbreviations
AHA: acquired hemophilia A; aPCC: activated prothrombin complex concentrate; aPTT: activated partial thromboplastin time; DDAVP: desmopressin; F: coagulation factor; FEIBA: factor VIII inhibitor bypassing activity; PT: prothrombin time; rF: recombinant factor.
Competing interests
PC has received honoraria for consulting or lecturing from Baxter, Novo Nordisk, Bayer and Ipsen, educational grants from Baxter and Bayer and institutional support from Baxter; FB has received honoraria for consulting or lecturing from Bayer HealthCare, and Novo Nordisk; AH-K has received honoraria for consulting or lecturing from Bayer HealthCare, Novo Nordisk and Wyeth; JI has received honoraria for consulting or lecturing from Baxter, Novo Nordisk, Bayer, Wyeth, educational grants from BioVitrum and institutional support from STER, Baxter and BioVitrum; CMK's institution receives research funding for clinical trials on his behalf from Baxter Immuno, Novo Nordisk, Octapharma, Grifols, Genentech and Bayer. He has received honoraria for consulting or lecturing from Wyeth, Octapharma, Bayer, Baxter Immuno, Ipsen and Novo Nordisk; MEMC has received honoraria for consulting or lecturing for Novo Nordisk, Grifols, Baxter and Wyeth. No other relevant financial associations are reported by the Thrombosis and Haemostasis section of the Haematology department at the Regional University Hospital of Carlos Haya, Malaga (Spain); MS reported no relevant financial associations; JSL has received honoraria for consulting from Baxter and Novo Nordisk, educational grants from Bayer and research grants from Ipsen and Novartis; HL has received honoraria for consulting or lecturing from Novo Nordisk.
Authors' contributions
FB, AH-K, HL, MEMC and JSL were present at one or both of two initial meetings to define the scope of the present manuscript and the published guidelines for specialist physicians. FB, JI, AH-K, HL, MEMC, MS and JSL were present during the first consensus meeting to present the results of the literature review process.
Three working groups were formed to write each section of both manuscripts; communication occurred electronically or by telephone: diagnosis (PC, JI, MS), hemorrhagic treatment (FB, CMK, JSL), inhibitor eradication (HL, AH-K, MEMC).
FB, JI, CMK, JSL, AH-K, HL and MEMC were present for the final consensus meeting on both guideline manuscripts. PC prepared the final draft of the manuscript, which was reviewed and approved by all authors. The opinions expressed in this manuscript are those of the authors alone. All authors had full access to all of the literature described here and take responsibility for the integrity of the data and the accuracy of the data analysis.
Support for literature searches, meeting organization and medical writing were provided by Physicians World Europe GmbH, Mannheim, Germany. Costs incurred for travel, hotel accommodation, meeting facilities, remote communication and manuscript preparation were supported by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A: Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.
Br J Haematol 2003, 121(1):21-35. PubMed Abstract | Publisher Full Text
Baillieres Clin Haematol 1998, 11(2):287-303. PubMed Abstract | Publisher Full Text
Kessler CM, Asatiani E: Acquired Inhibitors to Factor VIII.
In Textbook of Hemophilia Edited by Lee CA, Berntorp EE, Hoots WK, Aledort LM. 2007, 86-90.
Morrison AE, Ludlam CA: Acquired haemophilia and its management.
Br J Haematol 1995, 89(2):231-236. PubMed Abstract | Publisher Full Text
Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR: Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.
Blood 2007, 109(5):1870-1877. PubMed Abstract | Publisher Full Text
Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R: A population based, unselected, consecutive cohort of patients with acquired haemophilia A.
Br J Haematol 2004, 124(1):86-90. PubMed Abstract | Publisher Full Text
Borg JY, Levesque H, for the SACHA study group: Epidemiology and one-year outcomes in patients with acquired hemophilia in France.
J Thromb Haemost 2007., 5(suppl 1)
Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.
Thromb Haemost 1981, 45(3):200-203. PubMed Abstract
Collins PW: Treatment of acquired hemophilia A.
J Thromb Haemost 2007, 5(5):893-900. PubMed Abstract | Publisher Full Text
Hay CR, Brown S, Collins PW, Keeling DM, Liesner R: The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Br J Haematol 2006, 133(6):591-605. PubMed Abstract | Publisher Full Text
Baudo F, de Cataldo F: Acquired haemophilia in the elderly. In Blood Disorders in the Elderly. Edited by Balducci L, Ershler W, de Gaetano G. Cambridge: Cambridge University Press; 2007:389-407.
Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, Castellano ME, Shima M, St-Louis J: International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.
Haematologica 2009, 94(4):566-575. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H: Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force.
Chest 2006, 129(1):174-181. PubMed Abstract | Publisher Full Text
Morrison AE, Ludlam CA, Kessler C: Use of porcine factor VIII in the treatment of patients with acquired hemophilia.
Blood 1993, 81(6):1513-1520. PubMed Abstract | Publisher Full Text
Lottenberg R, Kentro TB, Kitchens CS: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy.
Arch Intern Med 1987, 147(6):1077-1081. PubMed Abstract | Publisher Full Text
Greaves M, Cohen H, MacHin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome.
Br J Haematol 2000, 109(4):704-715. PubMed Abstract | Publisher Full Text
Kasper CK: Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation.
Blood Coagul Fibrinolysis 1991, 2(suppl 1):7-10. PubMed Abstract
Lossing TS, Kasper CK, Feinstein DI: Detection of factor VIII inhibitors with the partial thromboplastin time.
Blood 1977, 49(5):793-797. PubMed Abstract | Publisher Full Text
Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I: A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Thromb Haemost 1998, 79(4):872-875. PubMed Abstract | Publisher Full Text
Franchini M, Lippi G: Acquired factor VIII inhibitors.
Blood 2008, 112(2):250-255. PubMed Abstract | Publisher Full Text
Hay CR, Negrier C, Ludlam CA: The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
Thromb Haemost 1997, 78(6):1463-1467. PubMed Abstract
Sumner MJ, Geldziler BD, Pedersen M, Seremetis S: Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.
Haemophilia 2007, 13(5):451-461. PubMed Abstract | Publisher Full Text
Sallah S: Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.
Haemophilia 2004, 10(2):169-173. PubMed Abstract | Publisher Full Text
Novo Nordisk Health Care AG: NovoSeven Summary of Product Characteristics.
Baxter Corp: FEIBA VH Anti-inhibitor coagulant complex Vapor Heated.
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E: A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
Blood 2007, 109(2):546-551. PubMed Abstract | Publisher Full Text
Kasper CK: Human factor VIII for bleeding in patients with inhibitors.
Vox Sang 1999, 77(Suppl 1):47-48. PubMed Abstract | Publisher Full Text
Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, Vetter H, Brackmann HH: Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.
Blood 2005, 105(6):2287-2293. PubMed Abstract | Publisher Full Text
Freedman J, Rand ML, Russell O, Davis C, Cheatley PL, Blanchette V, Garvey MB: Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII.
Transfusion 2003, 43(11):1508-1513. PubMed Abstract | Publisher Full Text
Muhm M, Grois N, Kier P, Stumpflen A, Kyrle P, Pabinger I, Bettelheim P, Hinterberger W, Lechner K: 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
Haemostasis 1990, 20(1):15-20. PubMed Abstract
de la Fuente B, Panek S, Hoyer LW: The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor.
Br J Haematol 1985, 59(1):127-131. PubMed Abstract | Publisher Full Text
Naorose-Abidi SM, Bond LR, Chitolie A, Bevan DH: Desmopressin therapy in patients with acquired factor VIII inhibitors.
Lancet 1988, 1(8581):366. PubMed Abstract | Publisher Full Text
Mudad R, Kane WH: DDAVP in acquired hemophilia A: case report and review of the literature.
Am J Hematol 1993, 43(4):295-299. PubMed Abstract | Publisher Full Text
Green D, Rademaker AW, Briet E: A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.
Thromb Haemost 1993, 70(5):753-757. PubMed Abstract
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP: Rituximab in the treatment of acquired factor VIII inhibitors.
Blood 2002, 100(9):3426-3428. PubMed Abstract | Publisher Full Text
Stasi R, Brunetti M, Stipa E, Amadori S: Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.
Blood 2004, 103(12):4424-4428. PubMed Abstract | Publisher Full Text
Franchini M: Rituximab in the treatment of adult acquired hemophilia A: a systematic review.
Crit Rev Oncol Hematol 2007, 63(1):47-52. PubMed Abstract | Publisher Full Text
Sohngen D, Specker C, Bach D, Kuntz BM, Burk M, Aul C, Kobbe G, Heyll A, Hollmig KA, Schneider W: Acquired factor VIII inhibitors in nonhemophilic patients.
Ann Hematol 1997, 74(2):89-93. PubMed Abstract | Publisher Full Text
Lian EC, Larcada AF, Chiu AY: Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor.
Ann Intern Med 1989, 110(10):774-778. PubMed Abstract
Shaffer LG, Phillips MD: Successful treatment of acquired hemophilia with oral immunosuppressive therapy.
Ann Intern Med 1997, 127(3):206-209. PubMed Abstract | Publisher Full Text
Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z: Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone.
Am J Hematol 2002, 69(4):294-295. PubMed Abstract | Publisher Full Text
Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, Jouan-Flahault C, Horellou MH, Leynadier F, Liozon E, et al.: Acquired hemophilia due to factor VIII inhibitors in 34 patients.
Am J Med 1998, 105(5):400-408. PubMed Abstract | Publisher Full Text
Huang YW, Saidi P, Philipp C: Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases.
Haemophilia 2004, 10(6):713-721. PubMed Abstract | Publisher Full Text
Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R, Lazarchick J: Rituximab in the treatment of acquired factor VIII inhibitors.
Thromb Haemost 2006, 96(1):84-87. PubMed Abstract | Publisher Full Text
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest 2004, 126(3 Suppl):338S-400S. PubMed Abstract | Publisher Full Text


text:
Citation Resources Limited (ASX: CTR) is oil and gas exploration and production company, with interests in two development and exploration blocks in the South Peten Basin in Guatemala. The company has successfully completed its first well, and is looking to increase its current production to 900 BOPD by the end of 2013, and 1,500 BOPD by the end of 2014
Citation Resources targets higher oil production with Atzam-5 development well in Guatemala
Citation Resources (ASX: CTR) will drill within the next few days the Atzam-5 development well in Guatemala that could allow it to meet its targeted production rate of more than 600 barrels of oil per day.
Atzam-5 is located 1,100 metres southeast of the Atzam-4 production well and is designed to test the same carbonate reservoir intervals.
It will be drilled to a target depth of about 4,100 feet to intersect the C18 and C19 carbonate reservoirs as the primary objectives as well as the current producing C17 carbonate reservoir.
The Harold Lee 500 drill rig now set up on location with the drilling mast set in place and auxiliary equipment now being connected.
Atzam-4 Production
Production from the Atzam-4 well has continued over the last six months with oil produced being sold under contract to Perenco Guatemala that generates pre-tax netbacks of approximately $55-60 per barrel.
The well is producing at about 110 to 120 barrels of oil per day following a planned maintenance program in late December.
Atzam-4 continues to produce from natural reservoir pressure without the need for a submersible pump to assist flow rates with no water production to date.
Operator Latin American Resources will increase the choke over a period of time to establish the optimal production rate for this producing carbonate section.
Independent reservoir engineers Ralph Davis have advised that the well could be produced at an optimal production rate of 466 bpd, whilst maintaining the reservoir's structure and integrity.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.


text:
This 3-day event will attract delegates fom all over the world. The GAA Congress is the prime decision making and legislative body for the Gaelic Athletic Association. Friday 22 March will see a range of workshops and display events held at various locations throughout the city centre, followed by an evening plenary session. Saturday will be spent in a plenary session followed by a banquet that evening. Sunday will consist of religious services and completion of the Congress programme.
World GAA Congress
Your Itinerary
World GAA Congress
22 March 2013 - 24 March 2013
The Venue 2013


text:
Each year, about 2.5 million people visit emergency rooms across America as a result of a traumatic brain injury or TBI, according to the U.S. Centers for Disease Control and Prevention. And those injuries contribute to the death of about 50,000 people annually.
Often, the injuries occur as a result of negligence on the part of others, whether it's a defective product or a fall at a carelessly maintained or dangerous property or a car accident.
Founding partner Joel J. Feller successfully litigated a brain injury lawsuit in Philadelphia that resulted in a recovery of $13 million for a man who suffered a brain injury in a two-vehicle collision. The client was severely brain injured in the crash and was not able to assist in his own case. But through the use of experts and accident reconstruction specialists, Feller demonstrated that the accident was caused by the other driver (read about this case).
Feller also recovered $9.75 million in a Philadelphia brain injury lawsuit for a high school student who suffered catastrophic injuries in a vehicle accident. The 18-year-old student was being transported to an event in a school van when the driver lost control of the vehicle and flipped it (read about this case).
Founding partner Robert Ross, a leading Philadelphia brain injury lawyer, won $10 million for a boy who went into anaphylactic shock, resulting in brain injury caused by an allergic reaction to peanuts. Ross argued at trial that the 8-year-old boy's pediatrician and allergist were negligent for failing to warn about the life-threatening nature of the allergy and because they didn't order an EpiPen, which could have prevented the incident. The case drew national attention as the first successfully litigated case in the U.S. in which the plaintiff knowingly ate a known allergen (read about this case).
Other notable victories by Ross Feller Casey brain injury attorneys include:
- $12 million settlement for a boy who was left brain damaged after error during heart surgery
- $6 million settlement for a boy who suffered a brain injury at a Pennsylvania hospital due to a delay in his delivery (read about this case)
- $5.2 million settlement for a young girl who suffered a brain injury as a result of improper monitoring for treatment of diabetes
- $4.2 million settlement for a man injured from delay in treatment for head injuries suffered in a boxing match
Falls are the leading cause of TBIs, accounting for more than 40 percent, followed by unintentional blunt trauma (being hit by an object), 15 percent, and motor vehicle accidents, 14 percent.
But a common misconception is that there must be a blow to the head to cause TBI. The mere thrust of the brain crushing against the skull often results in enough force to bruise, tear or cause bleeding that builds up pressure and results in traumatic brain injury. In many instances, a high impact involving jerking or shaking, such as on an amusement park ride or in a car accident, causes traumatic brain injury.
Those who survive a TBI can face effects lasting only a few days to disabilities that may remain for the rest of their lives. Effects can include impaired thinking or memory, movement, sensation, or emotional functioning, such as personality changes and depression. These issues not only affect individuals but can have lasting effects on families and others around them.
Ross Feller Casey has a nationally recognized team of doctor-lawyers right on staff -- an invaluable resource that uniquely positions the firm to handle all traumatic brain injury lawsuits and to help guide injured clients and their families through the legal process.
Ross Feller Casey is currently representing several clients throughout Pennsylvania, both adults and young children, who were victims of a delay in diagnosing meningitis, a potentially life-altering inflammation of the membranes surrounding the brain and spinal cord. The delay left these victims with catastrophic brain injuries. Learn More
The firm handles all brain injury cases on a contingency basis. There will never be a cost to you unless a financial recovery is made in your traumatic brain injury case.
If you or a loved one has suffered such an injury, a Philadelphia brain injury lawyer can assist you in determining if you have lawsuit. Even if the brain injury occurred some time ago, you may still be able to investigate a potential lawsuit. But your time may be running out.
Please contact our office for a free consultation with a traumatic brain injury lawyer in Philadelphia.


text:
in America
At least one person has died in a crash on Florida's Turnpike and the investigation has shut down northbound lanes in Orange County, according to Fire Rescue officials.
VERY CRITICAL PHASE OF JURY SELECTION IN THE GEORGE ZIMMERMAN TRIAL. FIRST THOUGH, FOLLOWING BREAKING NEWS OUT ON THE TURNPIKE WHERE AT LEAST ONE PERSON IS DEAD, AFTER A FIERY CRASH, I'M MATT AUSTIN, FLOOD HAVE YOUGLAD TOHAVE YOU WITH US. LET'S GO LIVE TO SKY 6 ON THE TURNPIKE NEAR ORANGE BLOSSOM TRAIL. DAVID SPRUNG IS RIGHT THERE. WHAT CAN YOU TELL US ABOUT THIS? Reporter: MATT, A SAD SCENE THIS AFTERNOON, RIGHT ON THE TURNPIKE, NORTHBOUND LANES RIGHT NOW ARE SHUT DOWN RIGHT NEAR THE 528-1792 AREA. TWO VEHICLES INVOLVED IN AN ACCIDENT, THE PICK UP TRUCK REAR ENDED A MINIVAN, YOU CAN SEE THE TRUCK WITH FRONT END DAMAGE. THE MINIVAN, THIS CAUSED THE PROBLEM. A CRUMPLED MESS, CAUGHT ON FIRE. FIRE DEPARTMENT GOT THE FIRE OUT BUT UNFORTUNATELY, ONE PERSON DID DIE IN THIS ACCIDENT.
No email address was supplied by
To complete your registration on this site, please supply an address.
Please confirm or modify the email address to which you will have subscription offers sent.
For a more personalized experience, please supply the following optional information.


text:
Son Of God is coming
PriscillaJan 23 2014,
Son of God comes to theaters February 28, 2014. Now, the larger-than-life story of The New Testament gets a larger-than life treatment in the stand-alone feature SON OF GOD. Told with the scope and scale of an action epic, the film features powerful performances, exotic locales, dazzling visual effects and a rich orchestral score from Oscar®-winner Hans Zimmer. Portuguese actor Diogo Morgado portrays Jesus as the film spans from his humble birth through his teachings, crucifixion and ultimate resurrection. It marks the first motion picture about Jesus's life since Passion of the Christ, released ten years ago.
Press the button
if you liked the video! Thank you!
We have all been judged - NOAH Movie Clipby Priscilla
Mar 28 2014, 498 views
Noah Movie - Ark Featuretteby heavensky
Mar 6 2014, 1,508 views
Noah - Official Trailer (2014) [HD] Russel Crowe, Emma Watsonby Priscilla
Mar 6 2014, 512 views
The actor Diogo Morgado did a good job or not in the movie Son of God? Click!by Priscilla
Feb 27 2014, 361 views
Geoff Tunnicliffe: the movie Son of God is a gift given to churchesby Priscilla
Feb 27 2014, 184 views
Editor's Pick
She records an album each year as a gift for her family each year. This time she really nailed it!by heavensky
Jul 25 2014, 3,430 views
Oh My Heart! These New Born Twins' First Conversation Put the Biggest Smile On My Face!by ProphesyGW
Jul 25 2014, 15,529 views
When This Homeless Lent His Bucket Out, What He Got Was Not Just A Nice Concert!by cancercross
Jul 25 2014, 5,928 views
This Little Puppy Has Finished An Impossible Race. I'm Nuts About Him!by ProphesyGW
Jul 25 2014, 1,460 views
I was scared when she put the baby into bath, But what happened next just stole my heart!by heavensky
Jul 24 2014, 21,716 views
These Two SHY Brothers Did Something that Amazed The Guests, I Was Floored!by thanksforlovingme
Jul 24 2014, 8,649 views


text:
Was so excited when I heard Prabal Gurung with doing a collection for Target. The collection called 'Love' did not disappoint. It launched yesterday and due to my stomach bug that I've been battling over the weekend, I was up at 4am on Sunday and found myself online shopping the collection. Early bird gets the worm because at the moment it is pretty much sold out everywhere in stores and online. The printed orchid floral scape sweatshirt was definitely number one on my list and I believe many others. It was sold out online but I found it at my local Target and I knew the collection wouldn't be picked clean at this particular Target since it was fairly new to the city. My best kept secret at the moment. I also got the multicolored printed shirt dress that is coming later. That one screamed my name when I saw it on the lookbook.
I didn't waste any time to wear my sweatshirt. I found every ounce of energy left in me to go to the Justin Timberlake concert last night in Hollywood. I thought the occasion was perfect for the sweatshirt and I am literally obsessed how it looks on and photographs. It is a stand out piece for sure and the price tag couldn't be beat.
Outfit of the night: Prabal Gurung x Target sweatshirt / T by Alexander Wang l/s tee / Isabel Marant mesh tuninc / Topshop leather pants / Isabel Marant sneakers (not pictured) / Chanel purse


text:
in this issue
premium services
online directory
customer care
World News and Views :: Top of the News
CVC Capital, RAG Plan Evonik IPO by 2013
June 4, 2008 | Nancy Seewald
CVC Capital Partners (London) and RAG (Essen, Germany) say they plan to launch an initial public offering (IPO) of Evonik Industries in the "medium term." The IPO will be launched between 2010 and 2013, according to news coverage of a press conference held by CVC and RAG today in Germany. CVC confirmed yesterday that it will acquire a 25% stake in Evonik for approximately €2.4 billion ($3.7 billion), pending antitrust approval. CVC beat out competing bids from Bain Capital, Blackstone Group, and Kohlberg Kravis Roberts. "There were several...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee
contact us | about us | customer care | privacy policy | sitemap | advertise
Copyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.


text:
See All
My Communities
My Discussions
My Email Digests
That said, if the redness becomes painful or cuts of any kind of circulation, there is itchiness or hives or persists, I'd contact my doc. Something else besides the microdermabrasion may be at work and your doc should know.View Thread
It has stolen any semblance of a life I had and reduced me to barely walking because of the pain from osteonecrosis and/or the shortness of breath caused by Shrinking Lung Syndrome. The shortness of breath is so severe that walking more than a block without a rest is unheard of.. Not walking those blocs has caused my weight to increase and increasing weight which increases the pressure put on my already compromised joints.
So, which came first, the chicken or the egg? All that I know is that this can't go on like this and I'm tempted work harder, EVER SO HARD on the weight.
AnnieView Thread
Last year I tried weight loss of nutrisystems and lost nearly 30 pounds. That was not a problem. Now, with no more money in the 'till' It's salads, salads, salads, and lean cuisine. Lance Armstrong's 'livestrong' was all that I needView Thread
However, those are not reasons not to get vaccinated; in fact, I just had tetanus (Tdap) yesterday and I've not had any problems. Ususally any side effects like that go away. None, the less, talk to your doctor about YOU SPECIFICALLY. I'd imagine if you've had a reaction to one vaccine in the past, you're more likely to h ave a reaction to another vaccine.
If you have allergies to certain vaccines, don't set yourself up for another allergic reaction. Talk to your doc about hivrd to shortness of breath or swelling of the lips; THESE ARE TRUE REACTIONS and reason not to get the vaccination.View Thread
That said, if you've given Cymbalta a good chance, there are other antidepressants and teyre are a lot of the, The one that has helped me is Celexa. but your doc knows you best.
Not much blood work can be done for things like CFS or fibromyalgia. This IS a board to complain on; lupus throws such a wrench into your life, so complain all you want. It's good for the soul@
'i don't know what else to do?" Well, starting to keep a diary is a good start, Keep track of what you at, and how you may feel. You may see a correlation between how you feel and food. But, lupus is a REAL disease. Just because you can't see it, makes it hard to win 'A BIT' of sympathy. I don't want sympathy from my family, but I'd at least like them to ARELView Thread
Currently taking CellCept and some days it''s all I can do to walk across a room. I'm trying to exercise and do so with the assistance of an exercise physiologit who knows how to maximize pulmonary gains without compromising osteonecrosis.
I see docs at National Jewish health in Denver who are considering adding theophilline to my regimen. But theophylline interacts with so many meds and I'm on a ton.View Thread
This does not go into the scientific detail that turns people off, yet it comprehensively explains the basics and symtpoms.
I use it a lot on my blog and in a newsletter that I write. No, you can't carry a video around most times. But you can send an e-mail link from you tube. AnnieView Thread
This is the first time I've thought it could be related to lupus. The ENT doc who evaluated me, told me that it can happen, too, if the little cilia (the hairs in the ears) break. I don't know what that does, but apparently if affects the sound..View Thread
I have some big doubts that I don't likel I like to give everything that comes down the pike a 'fair shot,' but it only stands to reason that more cannot be insured for the same amount of money and the quality stay the same, if not improved.
I don't have the money to raise my taxes (SSD) , and am chronically ill, so I know that my care costs a fair nickel.AnnieView Thread
AnnieView Thread
See Related Pain Management Communities
Women's Health Newsletter
Find out what women really need.
With Lupus
at work, or with family
and friends.
The opinions expressed in WebMD Communities are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. Communities are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions. Some of these opinions may contain information about treatments or uses of drug products that have not been approved by the U.S. Food and Drug Administration. WebMD does not endorse any specific product, service or treatment.
Do not consider Communities as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource, but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.
Health Solutions From Our Sponsors
©2005-2015 WebMD, LLC. All rights reserved.
WebMD does not provide medical advice, diagnosis or treatment. See additional information.


text:
This piece was created for our series "I Know He Is But Who Am I?"
The goal of this piece is to help people understand who God says they are through the grace and mercy of Jesus Christ.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?


text:
Political Organization Annual Reporting Requirements: Reporting Income in Part I of Form 990
How does a political organization report its income in Part VIII of Form 990?
That an item of income is treated as a contribution for purposes of election law reporting does not necessarily mean it is reported as a contribution on Form 990. Instead, the political organization must determine the various types of income it has and report each type on the appropriate lines in Parts VIII and I of Form 990. For example, membership dues and assessments are reported on line 1b, Part VIII, of the 2011 return, whereas political fundraising or entertainment event income is generally reported as income from fundraising events on line 1c. Unlike Form 1120-POL, all income of the political organization is reported on Form 990 (including contributions (line 1)) and taxable income (such as interest and dividends (Part VIII, lines 3-7 of the 2011 form)).
Additional information:
- Form 990, Return of Organization Exempt From Tax
- Form 990 instructions


text:
Dragon Ball Advanced Adventure
| |
Release Date: June 6, 2006
Dragon Ball Advanced Adventure Cheats & Codes
All | Cheats | Unlockables | Hints | Easter Eggs | Achievements
Check out our 1 cheat for Dragon Ball Advanced Adventure.
1 UnlockablesSubmit an Unlockable.
You must be Logged in to submit a cheat.
Game Details
Published by: Banpresto
Developed by: Dimps
Genre: Action
Release Date:
United States: June 6, 2006
Japan: November 18, 2004
E10+ for Everyone 10 and older : Cartoon Violence, Comic Mischief
Also Available On:
Games You May Like
- Action
- Game Boy Advance
Using the power of a mystical hat called The Minish Cap, the Hylian hero will shrink down for a massive quest... on a microscopic scale!
The famed Metroid series makes its return on the Game Boy Advance with Metroid Fusion. Experience a new and enthralling chapter in the…
Use combat strategies to help defeat Frieza and fulfill the Legacy of Goku, the greatest warrior the Universe has ever known!
An RPG similar to all the other main Pokemon titles: the story takes place over land and sea and pits you against Team Aqua and Team Magma.
POKÉMON RUBY and Sapphire take place in an all-new region known as Hoenn. When the game starts, you get to decide to control either a boy or…
We've seen the future, and it's all about Pokémon FireRed and Pokemon LeafGreen. The new games are set in Kanto, the region where Pokémon…


text:
Today is Deadline for Second Installment of Effingham County Property Tax Bill
Published on October 12 2012 10:05 am
Last Updated on July 14 2013 12:07 pm
Written by Greg Sapp
Today is the deadline to pay the second installment of your Effingham County property tax bill if you want avoid a 1-1/2% per month interest penalty for late payment of your bill.
The County Treasurer's office is located on the second floor of the Effingham County Office Building, west across the street from the old Courthouse. The office will be open until 4pm.
Take along your bill when making your payment. Look on the back of the bill for instructions if you'd like to pay your bill online.


text:
Originally posted on NFL Trade Rumors | Last updated 2/13/13
GREEN BAY, WI - JANUARY 12: Wide receiver Greg Jennings #85 of the Green Bay Packers celebrates with a 'Lambeau leap' after catching a two-yard touchdown pass in the second quarter against the Seattle Seahawks during the NFC divisional playoff game on January 12, 2008 at Lambeau Field in Green Bay, Wisconsin. The Packers defeated the Seahawks 42-20 to advance to the NFC championship game. (Photo by Jonathan Daniel/Getty Images)
Packers WR Greg Jennings joined the NFL Network on Wednesday and mentioned that he's open to anything this offseason. "All other 31 teams are an option," Jennings said, via NFL.com He's already put his house in Wisconsin on the market so he's more than prepared to be playing elsewhere next season. The Miami Dolphins have been consistently mentioned as a potential landing spot given their need for a receiver and the fact that he spent time with their current head coach Joe Philbin while he was in Green Bay. "I wouldn't mind that at all," Jennings said of playing for the Dolphins next season. "The weather's definitely nice. They have an up and coming quarterback." Ian Rapoport added that the Vikings, Rams and Colts could also have interest in Jennings during free agency. This is the first time we've heard the either the Rams or the Colts as speculative options. St Louis figures to have limited cap space to work, but could really use a true No. 1 receiver. Danny Amendola figures to be at the top of their offseason to-do list, and most likely could be retained for much less than Jennings. If they're considering adding more talent at wide receiver then it probably makes more sense to target someone in the draft given that there are more cost efficient options there. Indianapolis re-signed Reggie Wayne last year and he rewarded them with a very productive 2012 season. They also drafted T.Y. Hilton who was a pleasant surprise and provided them with a much needed deep threat. The Colts will have cap space to work with and it probably couldn't hurt to keep surrounding Andrew Luck with decent receivers, so we'll have to see if there's any real interest. Minnesota is very interesting to me. They'll have cap space to pursue Jennings and the current issues with Percy Harvin could force them to look for a replacement during offseason. Jennings is one of the best route-runners in the league and would give Minnesota a solid possession receiver to help Christian Ponder next season. Plus, he knows the Packers as well as anyone and the Vikings have been known to target players from NFC North teams in the past. We have Jennings listed as the No. 10 best available player in our Top 50 Free Agents list. The post Potential Landing Spots For WR Greg Jennings appeared first on NFL Trade Rumors -.
NFL News
Delivered to your inbox
You'll also receive Yardbarker's daily Top 10, featuring the best sports stories from around the web. Customize your newsletter to get articles on your favorite sports and teams. And the best part? It's free!
Follow us on Twitter
|Best of Yardbarker
|NFL News
|MLB News
Today's Best Stuff
For Publishers
Company Info
Follow Yardbarker
|© 2015 Yardbarker, Inc. All rights reserved. Use of this website (including any and all parts and components) constitutes your acceptance of these Terms of Use and Privacy Policy. (What's New?)


text:
Public Garden Career Center - View Job
New Media Manager
Category: Manager
Vizcaya Museum and Gardens
Miami, Florida
Posted: Monday, December 23, 2013
New Media Manager
Vizcaya Museum and Gardens
Vizcaya Museum and Gardens is a National Historic Landmark, accredited by the American Alliance of Museums and located on Miami's spectacular Biscayne Bay. Vizcaya consists of 14 historic buildings on 50 acres of grounds, with approximately 2,500 objects and 40,000 archival documents. The Museum attracts nearly 200,000 visitors annually and is working to strengthen and extend its profile as a cultural resource locally, regionally and nationally.
The position of New Media Manager will advance Vizcaya's institutional goals by engaging our culturally diverse community through a variety of new media tools and platforms. As a key member of the Museum's Advancement Division, this position will participate in planning and implementing marketing, membership, programmatic and fundraising strategies that capitalize upon Vizcaya's upcoming Centennial and a possible capital campaign. The position reports to the Marketing Director.
The New Media Manager will be responsible for: enhancing Vizcaya's brand and growing awareness of the Museum's programming areas; developing a cohesive and comprehensive social media program that is focused on digital content, usability and architecture; updating and managing all social media outlets, including regular postings on Facebook, Twitter, YouTube, Linkedin, Google+, Pinterest and blogs; maintaining the Museum's website, including new and updated content, installation of videos, audio slideshows, QR codes, wallpapers and other multimedia items; collaborating with colleagues to promote public program offerings and membership opportunities; researching and analyzing web analytics and social media traffic for weekly reports; and producing monthly email communications based on an annual editorial calendar focused on diverse stakeholders, members and prospective supporters.
Requirements: Bachelor's degree. One year of professional experience in communication, marketing and/or public relations to include experience with social media sites is required. Bilingual (English/Spanish) preferred, but not required.
Minimum Starting Salary: $42,790
Apply only at: http://www.miamidade.gov/humanresources/jobs.asp
No later than January 31, 2014
Job Opening ID: 20321
Hiring decisions are contingent upon the results of a physical examination, including alcohol/drug screening and background check. Equal Opportunity Employer/M/F/D/Veterans Preference.


text:
FREE SHIPPING with a $25 cosmetics purchase.
Use promo code BEAUTY25 for savings. Offer details
Clinique Lash Power Mascara Long Wearing Formula
Vows to look pretty for 24 hours without a smudge or smear. Lasts through rain, sweat, humidity and tears, yet washes off easily with warm water. .21-oz. Limit 1 order per day.
Tell a Friend
Other items in this collection
Vows to look pretty for 24 hours without a smudge or smear. One stroke and these pretty lashes last through rain, sweat, humidity, tears. Yet the formula removes easily with warm water. Unique brush reaches and beautifully lengthens even the tiniest lashes. Ophthalmologist tested.
How to Use:
Innovative thermal sensitive technology that helps it stay put for 24 hours is easy to remove. Use fingertips to splash warm water (39°C/103°F, bath temperature is ideal) on lashes several times and press gently. Or, wet a cotton pad with warm water, press to eye, then wipe away.
Works Well With:
- Cream Shaper for Eyes
- Color Surge Eye Shadow Duo
Additional information
Shipping & Delivery Details
Returning a purchase
Customer Service